The efficacy and safety of a daily oral administration of S06911 (strontium ranelate 2g/vitamin D3 1000 IU fixed combination) on vitamin D insufficiency in the treatment of osteoporotic postmenopausal women and men. A prospective, international phase III study with a 6-month double-blind period to assess the efficacy and safety of a daily oral administration of S06911 versus S12911 (strontium ranelate 2g) and a 6-month open-labelled extension for a subgroup of patients to assess safety of a daily oral administration of S06911.
Phase of Trial: Phase III
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Colecalciferol/strontium-ranelate (Primary) ; Strontium ranelate
- Indications Osteoporosis; Vitamin D deficiency
- Focus Therapeutic Use
- Sponsors Servier
- 23 Jun 2012 Official title amended as reported by European Clinical Trials Database.
- 29 Jul 2011 Actual end date (22 Jul 2011) added as reported by ISRCTN: Current Controlled Trials.
- 29 Jul 2011 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.